stockrow
Friday 6 November 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
65.55
0.12
−0.18%
Follow PTCT
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
8.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
7 | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 3 | 3 |
Altman Z-Score |
1.86 | (1.81) | (1.85) | (1.63) | (0.73) | 0.41 | 0.72 | 0.13 | (0.78) | (2.70) |
P/S ratio |
3.49 | 4.30 | 2.24 | 3.92 | 5.21 | 10.58 | 9.21 | 6.04 | 3.52 | 4.62 |
Altman Z″-Score (non-manufacturers) |
1.56 | (5.56) | (5.39) | (5.91) | (3.32) | (0.59) | (0.59) | (2.05) | (4.38) | (6.20) |
P/FCF ratio |
13.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(1.48) | (3.43) | (3.81) | (2.72) | (2.66) | (3.09) | (3.23) | (1.74) | 56.43 | (1.56) |
P/Operating CF |
(176.27) | (115.61) | (20.92) | (16.49) | (40.77) | (62.61) | (277.01) | (105.56) | 32.14 | (28.70) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 1,951.79 | 8.36 | 4.76 | 4.56 | 4.37 | 3.20 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.18 | 3.20 |
EV/Sales |
3.87 | 5.84 | 3.56 | 5.26 | 5.98 | 10.34 | 8.00 | 5.76 | 3.28 | 3.01 |
EV/EBITDA |
7.53 | 0.00 | 229.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
9.41 | (43.75) | (21.07) | (10.30) | (12.81) | (20.29) | (24.88) | (55.13) | (63.41) | (2.41) |
EV/FCF |
15.10 | (20.35) | (10.25) | (7.22) | (8.86) | (14.43) | (16.52) | (43.87) | (48.47) | (2.36) |
Quick Ratio |
2.20 | 2.23 | 1.72 | 1.39 | 1.74 | 4.23 | 3.15 | 1.77 | 2.82 | 5.17 |
Current Ratio |
2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
Net Debt/EBITDA |
0.73 | (15.80) | 85.07 | (3.33) | (1.36) | 0.27 | 1.77 | 0.83 | 1.01 | 1.05 |
Debt/Assets |
89.62% | 139.75% | 111.59% | 79.05% | 61.17% | 45.83% | 19.33% | 13.67% | 37.02% | 36.46% |
Debt/Equity |
(12.65) | (2.17) | (2.58) | (3.88) | 824.39 | 2.10 | 0.53 | 0.44 | 0.93 | 0.82 |
Asset Turnover |
0.75 | 0.45 | 0.52 | 0.38 | 0.26 | 0.20 | 0.22 | 0.35 | 0.59 | 0.26 |
Operating CF/Net income |
1.04 | 0.30 | 0.25 | 0.64 | 0.48 | 0.44 | 0.39 | 0.22 | 0.13 | 0.73 |
Capex/Depreciation |
(0.40) | (0.21) | (0.27) | (0.92) | (1.20) | (0.65) | (1.47) | (0.59) | (4.30) | (0.32) |
Interest Coverage |
5.69 | (1.81) | (3.40) | (4.92) | (4.35) | (7.66) | (19.31) | (9.21) | (5.32) | (15.96) |
| (104.75%) | 37.91% | 107.51% | 323.46% | (216.75%) | (81.42%) | (53.24%) | (50.51%) | (57.24%) | (82.24%) | |
| 29.66% | (20.18%) | (34.80%) | (30.68%) | (25.27%) | (22.87%) | (18.34%) | (16.95%) | (23.90%) | (44.79%) | |
ROIC |
121.13% | (130.42%) | (65.37%) | (47.36%) | (56.59%) | (69.14%) | (68.01%) | (26.18%) | (36.48%) | 0.00% |
Return on Tangible Assets |
50.16% | (42.97%) | (89.18%) | (155.22%) | (105.28%) | (44.34%) | (44.53%) | (76.81%) | (45.04%) | (64.86%) |
Average Days of Receivables |
38.30 | 71.73 | 62.59 | 81.28 | 74.85 | 67.03 | 66.03 | 93.63 | 75.85 | 110.02 |
Research and Development Expense of Revenue |
26.31% | 66.25% | 71.08% | 93.23% | 100.39% | 125.44% | 83.87% | 64.96% | 60.42% | 142.23% |
Selling, General and Administrative Expense of Revenue |
20.06% | 37.30% | 35.46% | 46.65% | 53.06% | 64.39% | 65.98% | 58.00% | 62.38% | 117.44% |
Intangible Assets out of Total Assets |
0.16 | 0.12 | 0.24 | 0.46 | 0.42 | 0.36 | 0.49 | 0.70 | 0.34 | 0.00 |
Share Based Compensation of Revenue |
4.31% | 9.25% | 10.84% | 15.79% | 19.22% | 18.47% | 13.73% | 12.56% | 15.72% | 42.33% |
Graham Net Nets |
(0.14) | (0.41) | (0.71) | (0.50) | (0.35) | (0.12) | (0.09) | (0.28) | 0.02 | 0.29 |
Graham Number |
0.00 | 39.00 | 45.36 | 29.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
11.57% | (10.48%) | (29.81%) | (20.41%) | (18.65%) | (10.98%) | (9.31%) | (7.84%) | (11.91%) | (37.13%) |
Free Cash Flow Yield |
7.34% | (6.67%) | (15.51%) | (18.60%) | (12.95%) | (6.77%) | (5.26%) | (2.17%) | (1.92%) | (27.55%) |
Revenue per Share |
21.76 | 10.50 | 12.53 | 9.74 | 7.64 | 5.77 | 5.22 | 5.68 | 4.96 | 2.43 |
Operating CF per Share |
8.94 | (1.40) | (2.12) | (4.97) | (3.57) | (2.94) | (1.68) | (0.59) | (0.26) | (3.04) |
Capex per Share |
(0.11) | (0.60) | (1.61) | (2.13) | (1.21) | (0.85) | (0.77) | (0.33) | (2.05) | (0.05) |
Free Cash Flow per Share |
8.83 | (2.00) | (3.73) | (7.10) | (4.78) | (3.79) | (2.45) | (0.93) | (2.31) | (3.09) |
Cash per Share |
24.46 | 14.83 | 11.72 | 5.73 | 10.98 | 16.71 | 11.66 | 4.89 | 4.88 | 6.80 |
Shareholders Equity per Share |
(2.58) | (14.29) | (10.94) | (4.84) | 0.02 | 7.30 | 10.10 | 7.53 | 3.99 | 3.51 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.58) | (14.29) | (10.94) | (4.84) | 0.02 | 7.30 | 10.10 | 7.53 | 3.99 | 3.51 |
Free Cash Flow |
702.41 | (153.88) | (279.04) | (509.11) | (336.66) | (250.05) | (144.08) | (43.17) | (90.33) | (105.34) |
Working Capital |
1,305.52 | 784.55 | 615.53 | 287.55 | 445.02 | 954.41 | 543.43 | 154.06 | 167.02 | 211.66 |
Capital Expenditures |
(8.79) | (46.19) | (120.62) | (152.46) | (85.33) | (55.98) | (45.44) | (15.53) | (80.26) | (1.78) |
Net Current Asset Value |
(830.13) | (1,437.56) | (1,495.62) | (1,358.92) | (982.25) | (494.55) | (250.17) | (447.64) | 13.85 | 111.52 |
EV/EBIT |
7.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.06 | 0.13 | 0.22 | 0.16 | 0.15 | 0.15 | 0.06 | 0.41 | 0.02 |
Price to Operating Income |
6.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.40 | 3.67 | 5.21 | 2.28 | 1.36 | 2.55 | 1.44 | 2.06 | 2.23 | 0.74 |
Cash ROIC |
16.19% | (6.35%) | (12.84%) | (36.06%) | (17.17%) | (9.63%) | (9.03%) | (5.90%) | (18.33%) | (23.44%) |
Accounts Receivable Turnover |
10.18 | 5.05 | 5.93 | 5.25 | 5.97 | 6.07 | 4.97 | 4.89 | 5.95 | 4.59 |
Accounts Payable Turnover |
0.14 | 0.16 | 0.18 | 0.15 | 0.12 | 0.09 | 0.08 | 0.12 | 0.07 | 0.00 |
Inventory Turnover |
0.91 | 2.13 | 2.50 | 2.37 | 1.87 | 1.00 | 0.69 | 0.94 | 0.34 | — |
Average Days of Payables |
2,960.12 | 1,935.03 | 2,184.80 | 2,617.25 | 3,260.52 | 4,666.42 | 4,790.75 | 3,693.18 | 6,096.31 | 0.00 |
Days of Inventory on Hand |
618.36 | 147.49 | 170.43 | 178.16 | 179.02 | 360.28 | 580.06 | 464.30 | 857.59 | — |
Average Receivables |
170.09 | 159.69 | 158.22 | 133.03 | 90.19 | 62.73 | 61.72 | 54.15 | 32.66 | 18.01 |
Average Payables |
342.78 | 348.14 | 356.17 | 304.58 | 265.48 | 200.72 | 143.74 | 102.32 | 62.60 | 47.00 |
Average Inventory |
51.42 | 26.89 | 26.19 | 18.83 | 17.28 | 18.99 | 17.70 | 13.44 | 13.50 | — |
Average Assets |
2,301.90 | 1,800.36 | 1,800.66 | 1,821.84 | 2,073.17 | 1,916.03 | 1,371.50 | 755.44 | 330.50 | 317.31 |
Average Common Equity |
(651.69) | (958.31) | (582.82) | (172.82) | 241.71 | 538.16 | 472.53 | 253.58 | 138.01 | 172.79 |
Columns are period end dates · fundamentals updated 6 Nov 2026